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Sir,
Daptomycin is a cyclic lipopeptide antibiotic, active against Gram-positive bacteria. It is excreted
unchanged primarily by the kidneys (78%)  and dosage adjustment is required in patients with renal
impairment 1. 
Daptomycin was shown to be substrate of P-glycoprotein (P-gp, MDR1) in vitro 2. P-gp is an efflux
transporter constitutively expressed in many human tissues with high levels in kidney and adrenal
glands where it has a major influence on drug disposition  3.  P-gp is encoded in humans by the
highly  polymorphic  ABCB1 gene  4.  For  example,  an  effect  of  single  nucleotide  polymorphism
(SNP)  in  ABCB1 on  the  pharmacokinetic  (PK)  profile  of  digoxin,  fexofenadine,  nelfinavir,
tacrolimus,  azytromycin,  cloxacillin,  rifampicin  was  reported  5,  6.  We  aimed  at  evaluating  the
influence of SNPs in ABCB1 on PK of daptomycin. 
Adult patients, presenting to Amedeo di Savoia Hospital (Turin, Italy), in therapy with intravenous
daptomycin according to the official indications were enrolled. Main exclusion criteria were: age
<18 years,  estimated creatinine clearance <30 mL/min,  septic shock, concomitant therapy with
drugs that  may inhibit  (indinavir,  nelfinavir,  ritonavir,  saquinavir,  erythromycin,  clarithromycin,
itraconazole) or induce (rifampicin, midazolam) P-gp function. The study was approved by ethics
committee (ASL TO-2, number 44824/13). Sampling was performed after written informed consent
was obtained. Blood samples for PK analysis were collected at steady state (after three days of
treatment) before dose and after 0.5, 1.5, 5, 9 and 24 h drug administration.
Genomic  DNA was  extracted  from  blood  using  the  QIAamp  DNA Mini  Kit  (Qiagen,  Venlo,
Netherlands). SNPs (3435 C>T, rs1045642; 1236 C>T, rs1128503; 2677 G>T, rs2032582 ) were
analyzed using  the  TaqMan assays  (Applied  Biosystems,  Foster  City,  CA)  by Real-Time PCR
(BIORAD, Hercules, CA) reaction.
Daptomycin plasma levels were assayed using two validated HPLC-MS and UPLC-PDA (Photo
Diode Array) methods  7,  8. Lower limit of quantification was 1.56 mg/L and 0.781 mg/L, for the
HPLC-MS and UPLC-PDA method, respectively. Intra and inter-day accuracy (CV%) and precision
(relative standard deviation, R.S.D.%) were lower than 15% for both methods. 
Area  under  the  curve  from  0  to  24h  (AUC0-24h),  volume  of  distribution  at  steady  state  (Vss),
clearance  at  steady  state  (CLss),  and  half  life  (t1/2)  were  estimated  using  Kinetica  5.0  software
(Thermo Scientific, Waltham, MA). 
A total of 23 Caucasians patients were included in the study: 16 patients (69.6%) were male.  
Median (interquartile range, IQR) age, weight, body mass index (BMI) were 61 years (46-71), 74 
kg (60-86), and 26 (21-29), respectively. Median daptomycin daily dosage was 6 mg/kg (5-7). 
Median (IQR) Cmax, Cmin, AUC0-24h, Vss, CLss, and t1/2 were: 97.1 mg/L (78.1-110.4), 15.0 mg/L (10.3-
21.8), 875.5 mg*h/L (634.4-1109.2), 8.7 L (6.8-9.9), 0.539 L/h (0.404-0.638), 11.0 h (8.4-12.1),
respectively.  At  linear  regression  analysis  using  Spearman’s  rank  correlation  a  trend  between
daptomycin dosage and AUC0-24h,  which is affected by CLss, was observed (ρ, 0.404; P= 0.056). In
order to evaluate the influence of genotype on daptomycin PK, we normalized Cmax,  Cmin, and AUC0-
24h for  daptomycin  dosage  (i.e.  AUC0-24h/dosage).  The allele  frequencies  for  3435T,  1236T,  and
2677T were  26.1%,  21.7%,  and 17.4%,  respectively.  Mann-Whitney test  indicated  that  median
dose- normalized AUC0-24h were higher in patients with 3435 TT genotype, compared with CC or CT
genotype (2.61 [1.96-3.14] versus 1.77 [1.51-1.98]; P=0.021). Similarly, CLss was lower in patients
with TT genotype compared to CC or CT genotype patients (0.38 [0.32-0.51] versus 0.57 [0.51-
0.66];  P=0.021)  (Figure  1).  Multiple  regression  analysis  showed  that  3435  TT was  the  only
individual factor predictive of dose-normalized AUC0-24h (P= 0.01) and clearance (P=0.012).
3435 C>T SNP is the only silent polymorphism that might influence P-gp expression in humans,
probably by altering protein folding and function and changing the substrate specificity  10. In this
study we found for the first time an influence of ABCB1 3435 C>T polymorphism on daptomycin
dose-normalized AUC0-24h and CLss.  The following limitations should be noted: low number of
patients, patients in treatment with different daptomycin dosage. These preliminary findings may
explain the high inter-subjects PK variability in daptomycin disposition and could represent the
starting point in individualization of therapy especially in patients with renal impairment. 
Part of these data were showed as oral presentation (A-1769) at the 52nd Interscience Conference on
Antimicrobial Agents and Chemotherapy (San Francisco, CA) . 
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Figure 1. Influence of  ABCB1 3435 C>T genotype on daptomycin dose normalized AUC0-24h (a)
and daptomycin clearance (b). AUC, area under the concentration-time curve; CLss, clearance at
steady state.
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